You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAripiprazole
Accession NumberDB01238  (APRD00638)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
Structure
Thumb
Synonyms
Abilify
Abilitat
Aripiprazol
Aripiprazole
Aripiprazolum
OPC 31
External Identifiers
  • OPC-14597
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abilifytablet30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not applicableUs
Abilifytablet2 mg/1oralCarilion Materials Management2002-11-15Not applicableUs
Abilifytablet20 mg/1oralCardinal Health2002-11-15Not applicableUs
Abilifytablet20 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-28Not applicableUs
Abilifytablet20 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
Abilifytablet2 mg/1oralSTAT Rx USA LLC2002-11-15Not applicableUs
Abilifytablet15 mg/1oralTYA Pharmaceuticals2002-11-15Not applicableUs
Abilifytablet5 mg/1oralbryant ranch prepack2002-11-15Not applicableUs
Abilifytablet30 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-15Not applicableUs
Abilifytablet15.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet2 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
Abilifytablet15 mg/1oralRebel Distributors Corp.2002-11-15Not applicableUs
Abilifytablet10 mg/1oralCardinal Health2002-11-15Not applicableUs
Abilifytablet2 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs
Abilifytablet2.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet15 mg/1oralCardinal Health2002-11-15Not applicableUs
Abilifytablet, orally disintegrating10 mg/1oralOtsuka America Pharmaceutical, Inc.2006-06-07Not applicableUs
Abilifytablet30 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
Abilifytablet5 mg/1oralSTAT Rx USA LLC2002-11-15Not applicableUs
Abilifytablet10 mg/1oralTYA Pharmaceuticals2002-11-15Not applicableUs
Abilifytablet5 mg/1oralH.J. Harkins Company, Inc.2002-11-15Not applicableUs
Abilifytablet10 mg/1oralbryant ranch prepack2002-11-15Not applicableUs
Abilifytablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not applicableUs
Abilifytablet20.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet5 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
Abilifytablet20 mg/1oralRebel Distributors Corp.2002-11-15Not applicableUs
Abilifytablet15 mg/1oralCarilion Materials Management2002-11-15Not applicableUs
Abilifytablet2 mg/1oralCardinal Health2002-11-15Not applicableUs
Abilifytablet, orally disintegrating15 mg/1oralOtsuka America Pharmaceutical, Inc.2006-06-07Not applicableUs
Abilifytablet10 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-15Not applicableUs
Abilifytablet5.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet30 mg/1oralCardinal Health2002-11-15Not applicableUs
Abilifysolution1 mg/mLoralOtsuka America Pharmaceutical, Inc.2004-12-10Not applicableUs
Abilifytablet5 mg/1oralRebel Distributors Corp.2002-11-15Not applicableUs
Abilifytablet10 mg/1oralPhysicians Total Care, Inc.2006-01-31Not applicableUs
Abilifytablet2 mg/1oralTYA Pharmaceuticals2002-11-15Not applicableUs
Abilifytablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not applicableUs
Abilifytablet30.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet10 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
Abilifytablet5 mg/1oralREMEDYREPACK INC.2013-05-102016-03-31Us
Abilifytablet5 mg/1oralCarilion Materials Management2002-11-15Not applicableUs
Abilifytablet5 mg/1oralCardinal Health2002-11-15Not applicableUs
Abilifytablet2 mg/1oralbryant ranch prepack2002-11-15Not applicableUs
Abilifytablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-15Not applicableUs
Abilifytablet10.0 mgoralBristol Myers Squibb Canada2009-09-30Not applicableCanada
Abilifytablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2002-11-15Not applicableUs
Abilifyinjection, solution9.75 mg/1.3mLintramuscularOtsuka America Pharmaceutical, Inc.2006-09-20Not applicableUs
Abilifytablet10 mg/1oralRebel Distributors Corp.2002-11-15Not applicableUs
Abilifytablet2 mg/1oralPhysicians Total Care, Inc.2011-07-18Not applicableUs
Abilifytablet5 mg/1oralTYA Pharmaceuticals2002-11-15Not applicableUs
Abilifytablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-06-03Not applicableUs
Abilifytablet15 mg/1oralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2014-10-08Not applicableUs
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection in pre-filled syringe300 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify Maintenapowder for suspension, sustained-release; kit400 mgintramuscularOtsuka Pharmaceutical Co Ltd2014-03-27Not applicableCanada
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2013-02-28Not applicableUs
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection400 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection in pre-filled syringe400 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection300 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2013-02-28Not applicableUs
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection in pre-filled syringe300 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection400 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenakitOtsuka America Pharmaceutical, Inc.2014-10-08Not applicableUs
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection in pre-filled syringe400 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaPowder and solvent for prolonged-release suspension for injection300 mgIntramuscular useOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify Maintenapowder for suspension, sustained-release; kit300 mgintramuscularOtsuka Pharmaceutical Co Ltd2014-03-27Not applicableCanada
Aristadainjection, suspension, extended release882 mg/3.2mLintramuscularAlkermes, Inc.2015-10-05Not applicableUs
Aristadainjection, suspension, extended release441 mg/1.6mLintramuscularAlkermes, Inc.2015-10-05Not applicableUs
Aristadainjection, suspension, extended release662 mg/2.4mLintramuscularAlkermes, Inc.2015-10-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abilifytablet15 mg/1oralREMEDYREPACK INC.2010-12-142015-12-29Us
Aripiprazoletablet15 mg/1oralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
Aripiprazoletablet30 mg/1oralSafecor Health, LLC2015-12-01Not applicableUs
Aripiprazoletablet5 mg/1oralMajor Pharmaceuticals2015-08-25Not applicableUs
Aripiprazoletablet2 mg/1oralAmerican Health Packaging2015-06-05Not applicableUs
Aripiprazoletablet15 mg/1oralAurobindo Pharma Limited2015-10-08Not applicableUs
Aripiprazoletablet20 mg/1oralTrigen Laboratories, LLC2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Aripiprazoletablet15 mg/1oralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet30 mg/1oralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet20 mg/1oralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazoletablet5 mg/1oralTeva Pharmaceuticals USA Inc2015-04-28Not applicableUs
Aripiprazolesolution1 mg/mLoralApotex Corp.2015-10-08Not applicableUs
Aripiprazoletablet10 mg/1oralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
Aripiprazoletablet30 mg/1oralMajor Pharmaceuticals2015-08-25Not applicableUs
Aripiprazoletablet20 mg/1oralAmerican Health Packaging2015-06-05Not applicableUs
Aripiprazoletablet5 mg/1oralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet2 mg/1oralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazoletablet10 mg/1oralSafecor Health, LLC2015-12-01Not applicableUs
Aripiprazoletablet30 mg/1oralTeva Pharmaceuticals USA Inc2015-04-28Not applicableUs
Aripiprazoletablet20 mg/1oralApotex Corp2015-07-24Not applicableUs
Aripiprazoletablet2 mg/1oralAurobindo Pharma Limited2015-10-08Not applicableUs
Aripiprazoletablet5 mg/1oralTrigen Laboratories, LLC2015-04-28Not applicableUs
Aripiprazoletablet2 mg/1oralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
Aripiprazoletablet10 mg/1oralMajor Pharmaceuticals2015-08-25Not applicableUs
Aripiprazoletablet5 mg/1oralAmerican Health Packaging2015-06-05Not applicableUs
Aripiprazoletablet20 mg/1oralAurobindo Pharma Limited2015-10-08Not applicableUs
Aripiprazoletablet30 mg/1oralTrigen Laboratories, LLC2015-04-28Not applicableUs
Aripiprazoletablet20 mg/1oralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
Aripiprazoletablet30 mg/1oralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazoletablet10 mg/1oralTeva Pharmaceuticals USA Inc2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralApotex Corp2015-07-24Not applicableUs
Aripiprazoletablet10 mg/1oralREMEDYREPACK INC.2015-12-08Not applicableUs
Aripiprazoletablet20 mg/1oralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet, orally disintegrating10 mg/1oralAlembic Pharmaceuticals Limited2015-05-21Not applicableUs
Aripiprazoletablet15 mg/1oralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
Aripiprazoletablet2 mg/1oralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet30 mg/1oralAmerican Health Packaging2015-06-05Not applicableUs
Aripiprazoletablet10 mg/1oralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazoletablet15 mg/1oralSafecor Health, LLC2015-12-01Not applicableUs
Aripiprazoletablet2 mg/1oralTeva Pharmaceuticals USA Inc2015-04-28Not applicableUs
Aripiprazoletablet30 mg/1oralApotex Corp2015-07-24Not applicableUs
Aripiprazoletablet5 mg/1oralAurobindo Pharma Limited2015-10-08Not applicableUs
Aripiprazoletablet10 mg/1oralTrigen Laboratories, LLC2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
Aripiprazoletablet2 mg/1oralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
Aripiprazoletablet15 mg/1oralMajor Pharmaceuticals2015-08-25Not applicableUs
Aripiprazoletablet10 mg/1oralAmerican Health Packaging2015-06-05Not applicableUs
Aripiprazoletablet30 mg/1oralAurobindo Pharma Limited2015-10-08Not applicableUs
Aripiprazoletablet, orally disintegrating10 mg/1oralTrigen Laboratories, LLC2015-05-21Not applicableUs
Aripiprazoletablet30 mg/1oralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
Aripiprazoletablet2 mg/1oralSafecor Health, LLC2015-12-01Not applicableUs
Aripiprazoletablet15 mg/1oralTeva Pharmaceuticals USA Inc2015-04-28Not applicableUs
Aripiprazoletablet10 mg/1oralApotex Corp2015-07-24Not applicableUs
Aripiprazoletablet20 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Aripiprazoletablet30 mg/1oralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet, orally disintegrating15 mg/1oralAlembic Pharmaceuticals Limited2015-05-21Not applicableUs
Aripiprazoletablet20 mg/1oralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
Aripiprazoletablet5 mg/1oralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralREMEDYREPACK INC.2015-05-19Not applicableUs
Aripiprazoletablet15 mg/1oralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet10 mg/1oralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazoletablet20 mg/1oralSafecor Health, LLC2015-12-01Not applicableUs
Aripiprazoletablet2 mg/1oralMajor Pharmaceuticals2015-08-25Not applicableUs
Aripiprazoletablet2 mg/1oralApotex Corp2015-07-24Not applicableUs
Aripiprazoletablet10 mg/1oralAurobindo Pharma Limited2015-10-08Not applicableUs
Aripiprazoletablet15 mg/1oralTrigen Laboratories, LLC2015-04-28Not applicableUs
Aripiprazoletablet10 mg/1oralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
Aripiprazoletablet20 mg/1oralMajor Pharmaceuticals2015-08-25Not applicableUs
Aripiprazoletablet15 mg/1oralAmerican Health Packaging2015-06-05Not applicableUs
Aripiprazoletablet2 mg/1oralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet, orally disintegrating15 mg/1oralTrigen Laboratories, LLC2015-05-21Not applicableUs
Aripiprazoletablet10 mg/1oralCarilion Materials Management2015-04-28Not applicableUs
Aripiprazoletablet5 mg/1oralSafecor Health, LLC2015-12-01Not applicableUs
Aripiprazoletablet20 mg/1oralTeva Pharmaceuticals USA Inc2015-04-28Not applicableUs
Aripiprazoletablet15 mg/1oralApotex Corp2015-07-24Not applicableUs
Aripiprazolesolution1 mg/mLoralAmneal Pharmaceuticals of New York, LLC2015-08-17Not applicableUs
Aripiprazoletablet2 mg/1oralTrigen Laboratories, LLC2015-04-28Not applicableUs
Aripiprazoletablet30 mg/1oralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
Aripiprazoletablet10 mg/1oralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet10 mg/1oralREMEDYREPACK INC.2015-06-16Not applicableUs
Aripiprazoletablet20 mg/1oralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
Aripiprazoletablet15 mg/1oralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOral useAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOral useMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Oral Solutionsolution1 mg/mLoralSilarx Pharmaceuticals, Inc2015-08-17Not applicableUs
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOral useSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole ZentivaTablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaOrodispersible tablet10 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOral useZentiva, K.S.2015-06-25Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbilitatNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Aripiprazole lauroxil
ThumbNot applicableDBSALT001351
Categories
UNII82VFR53I78
CAS number129722-12-9
WeightAverage: 448.385
Monoisotopic: 447.148032537
Chemical FormulaC23H27Cl2N3O2
InChI KeyInChIKey=CEUORZQYGODEFX-UHFFFAOYSA-N
InChI
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
IUPAC Name
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
SMILES
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Quinolone
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Substituted aniline
  • Dialkylarylamine
  • 1,2-dichlorobenzene
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
PharmacodynamicsAripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionAripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 4.9 L/kg
Protein binding>99%
Metabolism

Hepatic.

Route of eliminationLess than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
Half life75-146 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.992
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7431
P-glycoprotein inhibitor IInhibitor0.9585
P-glycoprotein inhibitor IIInhibitor0.9321
Renal organic cation transporterInhibitor0.5175
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6581
CYP450 2C9 inhibitorInhibitor0.6682
CYP450 2D6 inhibitorInhibitor0.6633
CYP450 2C19 inhibitorInhibitor0.8934
CYP450 3A4 inhibitorInhibitor0.5256
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9104
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.62
hERG inhibition (predictor II)Inhibitor0.8814
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular9.75 mg/1.3mL
Tabletoral10.0 mg
Tabletoral15.0 mg
Tabletoral2.0 mg
Tabletoral20.0 mg
Tabletoral30.0 mg
Tabletoral5.0 mg
Kit
Powder and solvent for prolonged-release suspension for injectionIntramuscular use300 mg
Powder and solvent for prolonged-release suspension for injectionIntramuscular use400 mg
Powder and solvent for prolonged-release suspension for injection in pre-filled syringeIntramuscular use300 mg
Powder and solvent for prolonged-release suspension for injection in pre-filled syringeIntramuscular use400 mg
Powder for suspension, sustained-release; kitintramuscular300 mg
Powder for suspension, sustained-release; kitintramuscular400 mg
Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral2 mg/1
Tabletoral20 mg/1
Tabletoral30 mg/1
Tabletoral5 mg/1
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral15 mg/1
TabletOral use10 mg
TabletOral use15 mg
TabletOral use30 mg
TabletOral use5 mg
Solutionoral1 mg/mL
TabletOral use20 mg
Orodispersible tabletOral use10 mg
Orodispersible tabletOral use15 mg
Orodispersible tabletOral use30 mg
Injection, suspension, extended releaseintramuscular441 mg/1.6mL
Injection, suspension, extended releaseintramuscular662 mg/2.4mL
Injection, suspension, extended releaseintramuscular882 mg/3.2mL
Prices
Unit descriptionCostUnit
Abilify Discmelt 30 10 mg Dispersible Tablet Box636.3USD box
Abilify 30 mg tablet32.12USD tablet
Abilify 15 mg tablet26.07USD tablet
Abilify 10 mg tablet23.53USD tablet
Abilify 5 mg tablet23.53USD tablet
Abilify 2 mg tablet22.25USD tablet
Abilify 20 mg tablet21.99USD tablet
Abilify discmelt 10 mg tablet20.39USD tablet
Abilify discmelt 15 mg tablet20.39USD tablet
Abilify 9.7 mg/1.3 ml vial16.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006528 No1994-10-202014-10-20Us
US6977257 Yes2002-10-242022-10-24Us
US7053092 No2002-01-282022-01-28Us
US7115587 Yes2005-01-212025-01-21Us
US7550445 Yes2005-01-212025-01-21Us
US7807680 No2004-10-192024-10-19Us
US8017615 Yes2004-12-162024-12-16Us
US8030313 No2004-10-192024-10-19Us
US8338427 No2005-03-152025-03-15Us
US8338428 No2003-08-062023-08-06Us
US8399469 No2005-06-292025-06-29Us
US8431576 No2010-10-262030-10-26Us
US8518421 Yes2001-07-242021-07-24Us
US8580796 Yes2003-03-252023-03-25Us
US8642600 Yes2002-07-282022-07-28Us
US8642760 Yes2003-03-252023-03-25Us
US8722679 No2004-10-192024-10-19Us
US8759350 No2007-03-022027-03-02Us
US8759351 No2003-08-062023-08-06Us
US8796276 No2010-06-242030-06-24Us
US8993761 No2002-09-252022-09-25Us
US9034867 No2012-11-072032-11-07Us
US9089567 No2002-01-282022-01-28Us
US9125939 No2006-07-282026-07-28Us
US9193685 No2013-10-242033-10-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00777 mg/mLALOGPS
logP5.21ALOGPS
logP4.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability49.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceUS5006528
General ReferencesNot Available
External Links
ATC CodesN05AX12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (262 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Aripiprazole can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole.
AcebutololThe serum concentration of Aripiprazole can be increased when it is combined with Acebutolol.
AcebutololAripiprazole may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.
AcetaminophenThe serum concentration of Aripiprazole can be decreased when it is combined with Acetaminophen.
AcetazolamideAripiprazole may increase the hypotensive activities of Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.
adipiplonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Aripiprazole.
AlclometasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Alclometasone.
AldesleukinAripiprazole may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Aripiprazole.
AlimemazineThe serum concentration of Aripiprazole can be decreased when it is combined with Alimemazine.
AliskirenAripiprazole may increase the hypotensive activities of Aliskiren.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphacetylmethadol.
AlprazolamThe serum concentration of Aripiprazole can be increased when it is combined with Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alprazolam.
AmilorideAripiprazole may increase the hypotensive activities of Amiloride.
AminoglutethimideThe serum concentration of Aripiprazole can be decreased when it is combined with Aminoglutethimide.
AmiodaroneThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.
AmiodaroneAripiprazole may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.
AmitriptylineThe serum concentration of Aripiprazole can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amitriptyline.
AmlodipineThe serum concentration of Aripiprazole can be increased when it is combined with Amlodipine.
AmlodipineAripiprazole may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amperozide.
AmphetamineAripiprazole may decrease the stimulatory activities of Amphetamine.
Amyl NitriteAripiprazole may increase the hypotensive activities of Amyl Nitrite.
AnagrelideAripiprazole may increase the QTc-prolonging activities of Anagrelide.
ApraclonidineAripiprazole may increase the hypotensive activities of Apraclonidine.
AprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Aprepitant.
ArmodafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil.
Arsenic trioxideAripiprazole may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherAripiprazole may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Aripiprazole can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Asenapine.
AtazanavirThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.
AtenololAripiprazole may increase the hypotensive activities of Atenolol.
AtomoxetineThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Aripiprazole can be increased when it is combined with Atorvastatin.
AvasimibeThe serum concentration of Aripiprazole can be decreased when it is combined with Avasimibe.
AzaperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azaperone.
AzatadineThe serum concentration of Aripiprazole can be decreased when it is combined with Azatadine.
AzelastineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Aripiprazole.
Azilsartan medoxomilAripiprazole may increase the hypotensive activities of Azilsartan medoxomil.
AzithromycinAripiprazole may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.
BedaquilineAripiprazole may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilAripiprazole may increase the hypotensive activities of Benazepril.
BendroflumethiazideAripiprazole may increase the hypotensive activities of Bendroflumethiazide.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Aripiprazole.
BenzphetamineAripiprazole may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzyl alcohol.
BetaxololThe serum concentration of Aripiprazole can be increased when it is combined with Betaxolol.
BetaxololAripiprazole may increase the hypotensive activities of Betaxolol.
BexaroteneThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Aripiprazole can be increased when it is combined with Bicalutamide.
BisoprololAripiprazole may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Aripiprazole can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Aripiprazole can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.
BretyliumAripiprazole may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brexpiprazole.
BrimonidineAripiprazole may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
BromazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aripiprazole.
BrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Aripiprazole.
BumetanideAripiprazole may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Aripiprazole.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Aripiprazole.
BupropionThe serum concentration of Aripiprazole can be increased when it is combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.
ButacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aripiprazole.
CalcitriolThe serum concentration of Aripiprazole can be decreased when it is combined with Calcitriol.
CanagliflozinAripiprazole may increase the hypotensive activities of Canagliflozin.
CandesartanAripiprazole may increase the hypotensive activities of Candesartan.
CaptoprilAripiprazole may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Aripiprazole.
CarbinoxamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.
CarteololAripiprazole may increase the hypotensive activities of Carteolol.
CarvedilolAripiprazole may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Aripiprazole.
CefradineThe serum concentration of Aripiprazole can be decreased when it is combined with Cefradine.
CelecoxibThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.
CeritinibThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.
CeritinibAripiprazole may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Cerivastatin.
CetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Aripiprazole.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aripiprazole.
ChloroquineThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.
ChloroquineAripiprazole may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideAripiprazole may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorphenamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorphenamine.
ChlorphenesinThe serum concentration of Aripiprazole can be decreased when it is combined with Chlorphenesin.
ChlorphentermineAripiprazole may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.
ChlorpromazineAripiprazole may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.
ChlorthalidoneAripiprazole may increase the hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone.
CholecalciferolThe serum concentration of Aripiprazole can be increased when it is combined with Cholecalciferol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Aripiprazole.
CilazaprilAripiprazole may increase the hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Aripiprazole can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aripiprazole.
CiprofloxacinThe serum concentration of Aripiprazole can be increased when it is combined with Ciprofloxacin.
CiprofloxacinAripiprazole may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideAripiprazole may increase the QTc-prolonging activities of Cisapride.
CitalopramThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Citalopram.
ClarithromycinThe serum concentration of Aripiprazole can be decreased when it is combined with Clarithromycin.
ClarithromycinAripiprazole may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe serum concentration of Aripiprazole can be increased when it is combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clemastine.
ClevidipineThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.
ClevidipineAripiprazole may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clidinium.
ClobazamThe serum concentration of Aripiprazole can be increased when it is combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clobazam.
ClofibrateThe serum concentration of Aripiprazole can be decreased when it is combined with Clofibrate.
clomethiazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with clomethiazole.
ClomipramineThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clonazepam.
ClonidineAripiprazole may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Aripiprazole.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.
ClotrimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Aripiprazole can be increased when it is combined with Clozapine.
ClozapineAripiprazole may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Aripiprazole can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Aripiprazole.
CodeineThe serum concentration of Aripiprazole can be increased when it is combined with Codeine.
CodeineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Codeine.
ColchicineThe serum concentration of Aripiprazole can be decreased when it is combined with Colchicine.
ConivaptanThe serum concentration of Aripiprazole can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Aripiprazole can be increased when it is combined with Crizotinib.
CrizotinibAripiprazole may increase the QTc-prolonging activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.
CyclophosphamideThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Aripiprazole can be increased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.
DalfopristinThe serum concentration of Aripiprazole can be increased when it is combined with Dalfopristin.
DanazolThe serum concentration of Aripiprazole can be increased when it is combined with Danazol.
DantroleneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.
DapagliflozinAripiprazole may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aripiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dapoxetine.
DarifenacinThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.
DarunavirThe serum concentration of Aripiprazole can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Aripiprazole can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Aripiprazole.
DesipramineThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aripiprazole.
DetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Detomidine.
DexamethasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.
DexmedetomidineAripiprazole may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aripiprazole.
DextroamphetamineAripiprazole may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe serum concentration of Aripiprazole can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aripiprazole.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Aripiprazole.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Aripiprazole.
DiclofenamideAripiprazole may increase the hypotensive activities of Diclofenamide.
DicloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Dicloxacillin.
DifenoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.
DihydroergotamineThe serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.
DiltiazemThe serum concentration of Aripiprazole can be increased when it is combined with Diltiazem.
DiltiazemAripiprazole may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimenhydrinate.
DinutuximabAripiprazole may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.
DipyridamoleAripiprazole may increase the hypotensive activities of Dipyridamole.
DisopyramideAripiprazole may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe serum concentration of Aripiprazole can be increased when it is combined with Disulfiram.
DofetilideAripiprazole may increase the QTc-prolonging activities of Dofetilide.
DolasetronThe serum concentration of Aripiprazole can be increased when it is combined with Dolasetron.
DolasetronAripiprazole may increase the QTc-prolonging activities of Dolasetron.
DomperidoneAripiprazole may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doramectin.
DoxazosinAripiprazole may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Aripiprazole.
DoxorubicinThe serum concentration of Aripiprazole can be increased when it is combined with Doxorubicin.
DoxycyclineThe serum concentration of Aripiprazole can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
DoxylamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Aripiprazole is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
DronedaroneThe serum concentration of Aripiprazole can be increased when it is combined with Dronedarone.
DronedaroneAripiprazole may increase the QTc-prolonging activities of Dronedarone.
DroperidolAripiprazole may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Aripiprazole.
DrotebanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.
DuloxetineThe serum concentration of Aripiprazole can be increased when it is combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole.
EcgonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Aripiprazole is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aripiprazole.
EliglustatThe serum concentration of Aripiprazole can be increased when it is combined with Eliglustat.
EliglustatAripiprazole may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinAripiprazole may increase the hypotensive activities of Empagliflozin.
EnalaprilAripiprazole may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Aripiprazole.
EntacaponeThe serum concentration of Aripiprazole can be increased when it is combined with Entacapone.
EntacaponeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Entacapone.
EnzalutamideThe serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.
EplerenoneAripiprazole may increase the hypotensive activities of Eplerenone.
EprosartanAripiprazole may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aripiprazole.
ErythromycinThe serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.
ErythromycinAripiprazole may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate.
EsmololAripiprazole may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Aripiprazole.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aripiprazole.
Etacrynic acidAripiprazole may increase the hypotensive activities of Etacrynic acid.
EthanolAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Aripiprazole.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole.
EthosuximideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Aripiprazole.
EtoperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etoperidone.
EtoposideThe serum concentration of Aripiprazole can be decreased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine.
EtravirineThe serum concentration of Aripiprazole can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Aripiprazole.
EzogabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Felbamate.
FelodipineThe serum concentration of Aripiprazole can be increased when it is combined with Felodipine.
FelodipineAripiprazole may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.
FexofenadineThe serum concentration of Aripiprazole can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fexofenadine.
FlecainideThe serum concentration of Aripiprazole can be increased when it is combined with Flecainide.
FlecainideAripiprazole may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.
FlucloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Flucloxacillin.
FluconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunitrazepam.
FluorometholoneThe serum concentration of Aripiprazole can be decreased when it is combined with Fluorometholone.
FluoxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aripiprazole.
FluphenazineThe serum concentration of Aripiprazole can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.
FluspirileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluticasone Propionate.
FluvastatinThe serum concentration of Aripiprazole can be increased when it is combined with Fluvastatin.
FluvoxamineThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Aripiprazole can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Fosaprepitant.
FosinoprilAripiprazole may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.
FurosemideAripiprazole may increase the hypotensive activities of Furosemide.
Fusidic AcidThe serum concentration of Aripiprazole can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aripiprazole.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with gabapentin enacarbil.
Gadobenic acidAripiprazole may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Aripiprazole can be increased when it is combined with Gefitinib.
GemfibrozilThe serum concentration of Aripiprazole can be decreased when it is combined with Gemfibrozil.
GemifloxacinAripiprazole may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Aripiprazole.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Aripiprazole.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.
GlutethimideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Aripiprazole.
Glycerol PhenylbutyrateThe serum concentration of Aripiprazole can be increased when it is combined with Glycerol Phenylbutyrate.
GoserelinAripiprazole may increase the QTc-prolonging activities of Goserelin.
GranisetronAripiprazole may increase the QTc-prolonging activities of Granisetron.
GriseofulvinThe serum concentration of Aripiprazole can be decreased when it is combined with Griseofulvin.
GuanethidineThe serum concentration of Aripiprazole can be decreased when it is combined with Guanethidine.
GuanfacineAripiprazole may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Aripiprazole.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Aripiprazole.
HaloperidolThe serum concentration of Aripiprazole can be increased when it is combined with Haloperidol.
HaloperidolAripiprazole may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Aripiprazole.
HeroinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexobarbital.
HydralazineAripiprazole may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Aripiprazole.
HydrocortamateThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortamate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.
Hydroxyamphetamine hydrobromideAripiprazole may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineThe serum concentration of Aripiprazole can be increased when it is combined with Hydroxyzine.
HydroxyzineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hydroxyzine.
IbutilideAripiprazole may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Aripiprazole can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Aripiprazole can be decreased when it is combined with Ifosfamide.
IloperidoneThe serum concentration of Aripiprazole can be increased when it is combined with Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Iloperidone.
ImatinibThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.
IndapamideAripiprazole may increase the hypotensive activities of Indapamide.
IndinavirThe serum concentration of Aripiprazole can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Aripiprazole.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Aripiprazole.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Aripiprazole.
IrbesartanThe serum concentration of Aripiprazole can be increased when it is combined with Irbesartan.
IrbesartanAripiprazole may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe serum concentration of Aripiprazole can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aripiprazole.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Aripiprazole.
IsoniazidThe serum concentration of Aripiprazole can be increased when it is combined with Isoniazid.
Isosorbide DinitrateAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateAripiprazole may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineAripiprazole may increase the hypotensive activities of Isoxsuprine.
IsradipineThe serum concentration of Aripiprazole can be increased when it is combined with Isradipine.
IsradipineAripiprazole may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.
KetazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.
KetoconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ketoconazole.
LabetalolAripiprazole may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lamotrigine.
LansoprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Aripiprazole can be increased when it is combined with Lapatinib.
LenvatinibAripiprazole may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideAripiprazole may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levetiracetam.
LevobunololAripiprazole may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Aripiprazole.
LevocabastineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levodopa.
LevofloxacinAripiprazole may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aripiprazole.
LevomilnacipranThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Aripiprazole.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Aripiprazole.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Aripiprazole.
LisdexamfetamineAripiprazole may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilAripiprazole may increase the hypotensive activities of Lisinopril.
LithiumLithium may increase the neurotoxic activities of Aripiprazole.
LithiumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lofentanil.
LomitapideThe serum concentration of Aripiprazole can be increased when it is combined with Lomitapide.
LomustineThe serum concentration of Aripiprazole can be increased when it is combined with Lomustine.
LopinavirThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.
LopinavirAripiprazole may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Aripiprazole can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.
LorcaserinThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.
LosartanAripiprazole may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Aripiprazole can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.
Lu AA21004The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lu AA21004.
LuliconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Aripiprazole can be increased when it is combined with Lumefantrine.
LumefantrineAripiprazole may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Magnesium Sulfate.
MannitolAripiprazole may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.
MecamylamineAripiprazole may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Medetomidine.
Medroxyprogesterone acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.
MefloquineThe serum concentration of Aripiprazole can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Aripiprazole.
MelperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Melperone.
MephentermineAripiprazole may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aripiprazole.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.
MequitazineAripiprazole may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aripiprazole.
MetamizoleThe serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.
MetaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.
MethadoneThe serum concentration of Aripiprazole can be increased when it is combined with Methadone.
MethadoneAripiprazole may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methadyl Acetate.
MethamphetamineAripiprazole may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methaqualone.
MethazolamideAripiprazole may increase the hypotensive activities of Methazolamide.
MethimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methimazole.
MethocarbamolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Aripiprazole.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methotrimeprazine.
MethoxsalenThe serum concentration of Aripiprazole can be increased when it is combined with Methoxsalen.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aripiprazole.
MethsuximideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.
MethyclothiazideAripiprazole may increase the hypotensive activities of Methyclothiazide.
MethyldopaAripiprazole may increase the hypotensive activities of Methyldopa.
MethylphenidateThe serum concentration of Aripiprazole can be increased when it is combined with Methylphenidate.
MethylphenidateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aripiprazole.
MetipranololAripiprazole may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.
MetolazoneAripiprazole may increase the hypotensive activities of Metolazone.
MetoprololThe serum concentration of Aripiprazole can be increased when it is combined with Metoprolol.
MetoprololAripiprazole may increase the hypotensive activities of Metoprolol.
MetyraponeThe serum concentration of Aripiprazole can be decreased when it is combined with Metyrapone.
MetyrosineAripiprazole may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Aripiprazole.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.
MifepristoneThe serum concentration of Aripiprazole can be increased when it is combined with Mifepristone.
MifepristoneAripiprazole may increase the QTc-prolonging activities of Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Aripiprazole.
MilnacipranThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
MinoxidilAripiprazole may increase the hypotensive activities of Minoxidil.
MirabegronThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.
MirtazapineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Aripiprazole.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Aripiprazole.
MitotaneThe serum concentration of Aripiprazole can be decreased when it is combined with Mitotane.
MoclobemideThe serum concentration of Aripiprazole can be increased when it is combined with Moclobemide.
ModafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Modafinil.
MoexiprilAripiprazole may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Aripiprazole.
MoxifloxacinAripiprazole may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
NabiloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nabilone.
NadololAripiprazole may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Aripiprazole can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aripiprazole.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole.
NebivololAripiprazole may increase the hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aripiprazole.
NelfinavirThe serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.
NesiritideAripiprazole may increase the hypotensive activities of Nesiritide.
NetupitantThe serum concentration of Aripiprazole can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Aripiprazole can be increased when it is combined with Nevirapine.
NicardipineThe serum concentration of Aripiprazole can be increased when it is combined with Nicardipine.
NicardipineAripiprazole may increase the hypotensive activities of Nicardipine.
NifedipineThe serum concentration of Aripiprazole can be increased when it is combined with Nifedipine.
NifedipineAripiprazole may increase the hypotensive activities of Nifedipine.
NilotinibThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.
NilotinibAripiprazole may increase the QTc-prolonging activities of Nilotinib.
NimodipineAripiprazole may increase the hypotensive activities of Nimodipine.
NisoldipineAripiprazole may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.
NitroglycerinAripiprazole may increase the hypotensive activities of Nitroglycerin.
NitroprussideAripiprazole may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Normethadone.
NortriptylineThe serum concentration of Aripiprazole can be increased when it is combined with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nortriptyline.
OfloxacinAripiprazole may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Aripiprazole can be increased when it is combined with Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olanzapine.
OlaparibThe serum concentration of Aripiprazole can be increased when it is combined with Olaparib.
OlmesartanAripiprazole may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.
OmeprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Omeprazole.
OndansetronThe serum concentration of Aripiprazole can be increased when it is combined with Ondansetron.
OndansetronAripiprazole may increase the QTc-prolonging activities of Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Opium.
OrlistatThe serum concentration of Aripiprazole can be decreased when it is combined with Orlistat.
OrphenadrineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Aripiprazole.
OsanetantThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.
OsimertinibThe serum concentration of Aripiprazole can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Aripiprazole can be increased when it is combined with Ospemifene.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.
OxcarbazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine.
OxiconazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Oxiconazole.
OxprenololThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Aripiprazole.
OxybutyninThe serum concentration of Aripiprazole can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aripiprazole.
PaclitaxelThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Paliperidone.
PanobinostatThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.
PanobinostatAripiprazole may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.
PapaverineAripiprazole may increase the hypotensive activities of Papaverine.
ParaldehydeAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Aripiprazole.
ParoxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Paroxetine.
PazopanibThe serum concentration of Aripiprazole can be increased when it is combined with Pazopanib.
PazopanibAripiprazole may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.
PegvisomantThe serum concentration of Aripiprazole can be decreased when it is combined with Pegvisomant.
PenbutololAripiprazole may increase the hypotensive activities of Penbutolol.
PentamidineThe serum concentration of Aripiprazole can be increased when it is combined with Pentamidine.
PentamidineAripiprazole may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Aripiprazole.
PerampanelThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perampanel.
PerflutrenAripiprazole may increase the QTc-prolonging activities of Perflutren.
PerindoprilAripiprazole may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perospirone.
PerphenazineThe serum concentration of Aripiprazole can be increased when it is combined with Perphenazine.
PerphenazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aripiprazole.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Aripiprazole.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aripiprazole.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoxyethanol.
PhentermineAripiprazole may decrease the stimulatory activities of Phentermine.
PhenylbutazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Phenylbutazone.
PhenytoinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Aripiprazole.
PindololThe serum concentration of Aripiprazole can be increased when it is combined with Pindolol.
PindololAripiprazole may increase the hypotensive activities of Pindolol.
PioglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Pioglitazone.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Aripiprazole.
PipamperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.
PosaconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.
PramipexoleAripiprazole may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Aripiprazole.
PramocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pramocaine.
PravastatinThe serum concentration of Aripiprazole can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.
PraziquantelThe serum concentration of Aripiprazole can be increased when it is combined with Praziquantel.
PrazosinAripiprazole may increase the hypotensive activities of Prazosin.
PrednisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Aripiprazole.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Aripiprazole.
PrimaquineThe serum concentration of Aripiprazole can be increased when it is combined with Primaquine.
PrimaquineAripiprazole may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Primidone.
ProbenecidThe serum concentration of Aripiprazole can be decreased when it is combined with Probenecid.
ProcainamideAripiprazole may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Aripiprazole.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.
ProgesteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.
PromazineThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.
PromazineAripiprazole may increase the QTc-prolonging activities of Promazine.
PromethazineThe serum concentration of Aripiprazole can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Promethazine.
PropafenoneThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.
PropafenoneAripiprazole may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aripiprazole.
PropofolThe serum concentration of Aripiprazole can be increased when it is combined with Propofol.
PropofolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propoxycaine.
PropranololThe serum concentration of Aripiprazole can be increased when it is combined with Propranolol.
PropranololAripiprazole may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Aripiprazole.
PSD502The risk or severity of adverse effects can be increased when Aripiprazole is combined with PSD502.
PyridostigmineThe serum concentration of Aripiprazole can be decreased when it is combined with Pyridostigmine.
QuazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.
QuetiapineAripiprazole may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aripiprazole.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aripiprazole.
QuinaprilAripiprazole may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.
QuinidineAripiprazole may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Aripiprazole can be increased when it is combined with Quinine.
QuinineAripiprazole may increase the QTc-prolonging activities of Quinine.
QuinupristinThe serum concentration of Aripiprazole can be increased when it is combined with Quinupristin.
RabeprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon.
RamiprilAripiprazole may increase the hypotensive activities of Ramipril.
RanitidineThe serum concentration of Aripiprazole can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Aripiprazole can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aripiprazole.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aripiprazole.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aripiprazole.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.
ReserpineAripiprazole may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Aripiprazole.
RifabutinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Aripiprazole can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifaximin.
RilpivirineThe serum concentration of Aripiprazole can be decreased when it is combined with Rilpivirine.
RiociguatAripiprazole may increase the hypotensive activities of Riociguat.
RisperidoneThe serum concentration of Aripiprazole can be increased when it is combined with Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Risperidone.
RitonavirThe serum concentration of Aripiprazole can be decreased when it is combined with Ritonavir.
RitonavirThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.
RofecoxibThe serum concentration of Aripiprazole can be decreased when it is combined with Rofecoxib.
RolapitantThe serum concentration of Aripiprazole can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Romifidine.
RopiniroleAripiprazole may increase the sedative activities of Ropinirole.
RopiniroleThe serum concentration of Aripiprazole can be increased when it is combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Aripiprazole.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole.
RotigotineAripiprazole may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Aripiprazole.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Aripiprazole is combined with S-Ethylisothiourea.
SaquinavirThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.
SaquinavirAripiprazole may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.
ScopolamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.
SelegilineThe serum concentration of Aripiprazole can be increased when it is combined with Selegiline.
SeratrodastThe serum concentration of Aripiprazole can be decreased when it is combined with Seratrodast.
SertindoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertindole.
SertralineThe serum concentration of Aripiprazole can be increased when it is combined with Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aripiprazole.
SildenafilThe serum concentration of Aripiprazole can be increased when it is combined with Sildenafil.
SiltuximabThe serum concentration of Aripiprazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Aripiprazole can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Aripiprazole can be increased when it is combined with Simvastatin.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.
Sodium oxybateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sodium oxybate.
Sodium phenylbutyrateThe serum concentration of Aripiprazole can be increased when it is combined with Sodium phenylbutyrate.
SotalolAripiprazole may increase the hypotensive activities of Sotalol.
SpironolactoneAripiprazole may increase the hypotensive activities of Spironolactone.
St. John's WortThe serum concentration of Aripiprazole can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aripiprazole.
SulconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulconazole.
SulfinpyrazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulfisoxazole.
SulfisoxazoleAripiprazole may increase the QTc-prolonging activities of Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aripiprazole.
SulpirideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.
SuvorexantThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Suvorexant.
TamoxifenThe serum concentration of Aripiprazole can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Aripiprazole.
TasimelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aripiprazole.
TelaprevirThe serum concentration of Aripiprazole can be increased when it is combined with Telaprevir.
TelavancinAripiprazole may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Telithromycin.
TelithromycinAripiprazole may increase the QTc-prolonging activities of Telithromycin.
TelmisartanAripiprazole may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.
TemozolomideThe serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide.
TemsirolimusThe serum concentration of Aripiprazole can be increased when it is combined with Temsirolimus.
TerazosinAripiprazole may increase the hypotensive activities of Terazosin.
TerbinafineThe serum concentration of Aripiprazole can be decreased when it is combined with Terbinafine.
TerfenadineThe serum concentration of Aripiprazole can be decreased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Aripiprazole can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.
TetracaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrodotoxin.
ThalidomideAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Aripiprazole.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aripiprazole.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Aripiprazole.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Aripiprazole.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aripiprazole.
ThiothixeneThe serum concentration of Aripiprazole can be increased when it is combined with Thiothixene.
ThiothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine.
TicagrelorThe serum concentration of Aripiprazole can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Aripiprazole can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiletamine.
TimololThe serum concentration of Aripiprazole can be increased when it is combined with Timolol.
TimololAripiprazole may increase the hypotensive activities of Timolol.
TioconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tioconazole.
TipranavirThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.
TizanidineAripiprazole may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aripiprazole.
TocilizumabThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.
TolcaponeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Topiramate.
TopotecanThe serum concentration of Aripiprazole can be decreased when it is combined with Topotecan.
TorasemideAripiprazole may increase the hypotensive activities of Torasemide.
ToremifeneAripiprazole may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.
TrametinibThe serum concentration of Aripiprazole can be decreased when it is combined with Trametinib.
TrandolaprilAripiprazole may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trazodone.
TriamtereneAripiprazole may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aripiprazole.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aripiprazole.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aripiprazole.
TriprolidineThe serum concentration of Aripiprazole can be increased when it is combined with Triprolidine.
TriprolidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triprolidine.
TroglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Troglitazone.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Aripiprazole.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Aripiprazole.
ValsartanAripiprazole may increase the hypotensive activities of Valsartan.
VandetanibAripiprazole may increase the QTc-prolonging activities of Vandetanib.
VemurafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Vemurafenib.
VemurafenibAripiprazole may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.
VerapamilAripiprazole may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vigabatrin.
VilazodoneThe serum concentration of Aripiprazole can be increased when it is combined with Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.
VinblastineThe serum concentration of Aripiprazole can be increased when it is combined with Vinblastine.
VinorelbineThe serum concentration of Aripiprazole can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Aripiprazole.
VoriconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Xylazine.
ZafirlukastThe serum concentration of Aripiprazole can be increased when it is combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.
ZiconotideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zimelidine.
ZiprasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Aripiprazole.
ZonisamideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Aripiprazole.
ZotepineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol (possible additive effect to CNS).
  • Food has no significant effect on absorption.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. [PubMed:14642974 ]
  2. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925 ]
  3. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30. [PubMed:17265076 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistpartial agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90. [PubMed:16366516 ]
  2. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11. [PubMed:9083792 ]
  3. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21. [PubMed:16925992 ]
  4. Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28. [PubMed:16981227 ]
  5. Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. [PubMed:17501690 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40. [PubMed:12063084 ]
  2. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28. [PubMed:14647959 ]
  3. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53. [PubMed:14709325 ]
  4. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. [PubMed:15257633 ]
  5. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41. [PubMed:15862515 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonistother/unknown
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38